AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

NCT03127449 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

116

Enrollment

INDUSTRY

Sponsor class

Stopped Indications have been approved for marketing

Conditions

Advanced NSCLC

Interventions

DRUG: Alflutinib

Sponsor

Allist Pharmaceuticals, Inc.